Conquer Cancer through AI

Lunit to Expand

MENU

1. Lunit Insight

- Lunit Insight MMG, the first AI solution for breast cancer screening, received its 510(k) clearance from the U.S. Food and Drug Administration (FDA) on Jan. 13, 2026.
- Powered by advanced AI, Lunit Insight MMG supports radiologists in detecting and classifying breast cancer lesions with high accuracy.
- LUNIT JOINT PROGRAM with research with institutions in the United States and Europe to validate clinical performance.
- Lunit Insight MMG is designed to integrate seamlessly into clinical workflows, enhancing Screening, Lesion Localization and Characterization.
- Lunit Insight MMG is expected to be commercialized in the U.S. and European markets in early and mid-2026, respectively.

2. Major Activities

Achieved KRW 342.2 billion in 2025 revenue, thriving by the impact of its AI solutions for cancer diagnosis and treatment, and expanding its SCARLETO platform for cancer genomic analysis

- Lunit achieved KRW 342.2 billion (USD 236.1 million) in revenue, a 29.5% increase year-over-year (YoY), and reached a record high for annual revenue.
- Driven by growth in its core AI solutions for cancer diagnosis and treatment, Lunit's core business also grew. Although operating loss widened to KRW 71.7 billion, the company maintained a strong cash position of KRW 1.1 trillion.

Lunit Revenue Trends

2025 Q1-Q4 KRW, Lunit Consolidated. The company's annual revenue surpassed KRW 300 billion for the first time, with overseas revenue accounting for about 90% of total revenue, although operating loss widened to KRW 71.7 billion, reflecting continued investments in R&D and global expansion.

Overseas revenue accounted for approximately 90% of total revenue. The acquisition of Gauss Health, Thirona's, which devices a coronaryheart calcium scoring solution, and the launch of Lunit Insight MMG, a mammography AI solution, contributed to growth in the company's core business.

Lunit's AI solutions for cancer diagnosis and treatment, including VUNO Med, saw YoY increases of 34%. The growth was driven by the adoption of Lunit Insight MMG and the commercialization of Lunit Insight CT, which contributed KRW 17.1 billion in sales, up from KRW 9.7 billion in 2024.

Lunit Insight MMG, the first AI solution for breast cancer screening, received its 510(k) clearance from the U.S. Food and Drug Administration (FDA)

2025-01-13 KST, Lunit Consolidated. The company's annual revenue surpassed KRW 300 billion for the first time, with overseas revenue accounting for about 90% of total revenue, although operating loss widened to KRW 71.7 billion, reflecting continued investments in R&D and global expansion.

Overseas revenue accounted for approximately 90% of total revenue. The acquisition of Gauss Health, Thirona's, which devices a coronaryheart calcium scoring solution, and the launch of Lunit Insight MMG, a mammography AI solution, contributed to growth in the company's core business.

Lunit's AI solutions for cancer diagnosis and treatment, including VUNO Med, saw YoY increases of 34%. The growth was driven by the adoption of Lunit Insight MMG and the commercialization of Lunit Insight CT, which contributed KRW 17.1 billion in sales, up from KRW 9.7 billion in 2024.

Lunit Insight MMG, the first AI solution for breast cancer screening, received its 510(k) clearance from the U.S. Food and Drug Administration (FDA)

2025-01-13 KST, Lunit Consolidated. The company's annual revenue surpassed KRW 300 billion for the first time, with overseas revenue accounting for about 90% of total revenue, although operating loss widened to KRW 71.7 billion, reflecting continued investments in R&D and global expansion.

Overseas revenue accounted for approximately 90% of total revenue. The acquisition of Gauss Health, Thirona's, which devices a coronaryheart calcium scoring solution, and the launch of Lunit Insight MMG, a mammography AI solution, contributed to growth in the company's core business.

Lunit's AI solutions for cancer diagnosis and treatment, including VUNO Med, saw YoY increases of 34%. The growth was driven by the adoption of Lunit Insight MMG and the commercialization of Lunit Insight CT, which contributed KRW 17.1 billion in sales, up from KRW 9.7 billion in 2024.

Lunit Insight MMG, the first AI solution for breast cancer screening, received its 510(k) clearance from the U.S. Food and Drug Administration (FDA)

2025-01-13 KST, Lunit Consolidated. The company's annual revenue surpassed KRW 300 billion for the first time, with overseas revenue accounting for about 90% of total revenue, although operating loss widened to KRW 71.7 billion, reflecting continued investments in R&D and global expansion.

Overseas revenue accounted for approximately 90% of total revenue. The acquisition of Gauss Health, Thirona's, which devices a coronaryheart calcium scoring solution, and the launch of Lunit Insight MMG, a mammography AI solution, contributed to growth in the company's core business.

Lunit's AI solutions for cancer diagnosis and treatment, including VUNO Med, saw YoY increases of 34%. The growth was driven by the adoption of Lunit Insight MMG and the commercialization of Lunit Insight CT, which contributed KRW 17.1 billion in sales, up from KRW 9.7 billion in 2024.

Lunit Insight MMG, the first AI solution for breast cancer screening, received its 510(k) clearance from the U.S. Food and Drug Administration (FDA)

2025-01-13 KST, Lunit Consolidated. The company's annual revenue surpassed KRW 300 billion for the first time, with overseas revenue accounting for about 90% of total revenue, although operating loss widened to KRW 71.7 billion, reflecting continued investments in R&D and global expansion.

Overseas revenue accounted for approximately 90% of total revenue. The acquisition of Gauss Health, Thirona's, which devices a coronaryheart calcium scoring solution, and the launch of Lunit Insight MMG, a mammography AI solution, contributed to growth in the company's core business.

Lunit's AI solutions for cancer diagnosis and treatment, including VUNO Med, saw YoY increases of 34%. The growth was driven by the adoption of Lunit Insight MMG and the commercialization of Lunit Insight CT, which contributed KRW 17.1 billion in sales, up from KRW 9.7 billion in 2024.

Lunit Insight MMG, the first AI solution for breast cancer screening, received its 510(k) clearance from the U.S. Food and Drug Administration (FDA)

3. Company

Achieved KRW 342.2 billion in 2025 revenue, thriving by the impact of its AI solutions for cancer diagnosis and treatment, and expanding its SCARLETO platform for cancer genomic analysis

- Lunit achieved KRW 342.2 billion (USD 236.1 million) in revenue, a 29.5% increase year-over-year (YoY), and reached a record high for annual revenue.
- Driven by growth in its core AI solutions for cancer diagnosis and treatment, Lunit's core business also grew. Although operating loss widened to KRW 71.7 billion, the company maintained a strong cash position of KRW 1.1 trillion.

Lunit Revenue Trends

2025-01-13 KST, Lunit Consolidated. The company's annual revenue surpassed KRW 300 billion for the first time, with overseas revenue accounting for about 90% of total revenue, although operating loss widened to KRW 71.7 billion, reflecting continued investments in R&D and global expansion.

Overseas revenue accounted for approximately 90% of total revenue. The acquisition of Gauss Health, Thirona's, which devices a coronaryheart calcium scoring solution, and the launch of Lunit Insight MMG, a mammography AI solution, contributed to growth in the company's core business.

Lunit's AI solutions for cancer diagnosis and treatment, including VUNO Med, saw YoY increases of 34%. The growth was driven by the adoption of Lunit Insight MMG and the commercialization of Lunit Insight CT, which contributed KRW 17.1 billion in sales, up from KRW 9.7 billion in 2024.

Lunit Insight MMG, the first AI solution for breast cancer screening, received its 510(k) clearance from the U.S. Food and Drug Administration (FDA)

4. News

Essential partnerships with Seoul National Hospital medical group, HMC, to deploy Lunit INSIGHT CXR. Strengthening presence in the Middle East

Selected for UAE Abu Dhabi's National Breast Cancer Screening study. Completed pilot phase, confirmed clinical relevance and signed official contract

2026-04-06 The Company signed a contract with Abu Dhabi Health Services Company (SEHA), the largest healthcare network in the UAE, to apply Lunit's AI solutions to the country's national breast cancer screening program.

The project expands use of the AI system of Lunit's AI solution to a national screening program covering about 1.5 million people, marking a significant step in the company's expansion into the Middle East healthcare market.

Over the last few years, SEHA plans to expand more than 200,000 mammograms per year, aiming to detect cancer at an early stage and reduce the burden on healthcare systems. Lunit's AI is a huge asset for the Company's AI vendor. Lunitby deploy Abu Dhabi's national breast cancer screening program, the Company's AI solution will be used in real-world clinical practice.

Lunit's AI solution for Pathology Suite for Analyzing Pathology Image" related to Lunit SCORPIO-PDL1 Scoring. Enables quantitative PD-L1 analysis to improve survival outcomes

2026-03-31 The Company has a product in U. aiming to develop the company's AI solution for pathology image analysis, Lunit SCORPIO-PDL1 Scoring, to enable quantitative PD-L1 analysis.

PD-L1 is widely used as a biomarker to predict cancer patient response to immunotherapy treatments. However, it has been difficult to accurately quantify PD-L1 expression using conventional methods, which has been a key limitation in its clinical application. Lunit's AI solution is designed to address this challenge.

The latest breakthrough Lunit achieved in collaboration with Seoul National Hospital and Seoul National University Hospital, which demonstrated that AI-based pathology analysis can predict immunotherapy response in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab, suggesting that PD-L1 quantification using AI may enable more precise patient selection for immunotherapy treatment.

The latest partner the Company recent focused on developing collaborations with major pathology laboratories and companies in the U.S. and Europe.

2. Regulatory Agreement

Received regulatory approval for Lunit INSIGHT CXR and MMG in Bangladesh. Expanding presence in South Asia

2026-03-31 The Company obtained the regulatory approval for its AI solutions from the Bangladesh Medical Research Council (BMRC). The company's AI solutions, Lunit INSIGHT CXR and Lunit INSIGHT MMG, are now officially approved for use in Bangladesh.

Building on this milestone, the Company is actively expanding its commercial presence in Bangladesh and the broader South Asian region.

To date, the Lunit SCORPIO-PDL1 AI solution has received regulatory approval in 7 countries, including the United States, Europe, Japan, Taiwan, Brazil, Canada, and Bangladesh.

3. Research

Launched exclusive research program with the world's largest pathology laboratory network, Lunit SCORPIO-PDL1 AI solution. Supporting drug development in a promising immunotherapy response

2026-03-31 The Company has signed a research collaboration with Sonic Healthcare, the world's largest pathology laboratory network, to develop and validate Lunit SCORPIO-PDL1 AI solution for lung cancer.

Sonic has a global footprint of over 1,000 laboratories in 10 countries, including Australia, the U.S., and Germany. Leveraging this network, Lunit SCORPIO-PDL1 AI solution will be used to support drug development and patient selection for immunotherapy treatments, enhancing its potential to deliver more precise and scalable diagnostic solutions.

Sonic's extensive network and its deep relationships with pharmaceutical companies are expected to accelerate the adoption of Lunit SCORPIO-PDL1 AI solution for lung cancer diagnostics. Lunit SCORPIO-PDL1 AI solution has demonstrated strong performance in predicting response to immunotherapy treatments, including PD-L1 expression and tumor mutational burden (TMB), which are widely used as key biomarkers in immunotherapy treatment decisions.

Lunit SCORPIO-PDL1 AI solution has also received regulatory approval in multiple countries, including the United States, Europe, Japan, Taiwan, Brazil, Canada, and Bangladesh. The company is actively expanding its commercial presence in these regions.

Lunit SCORPIO-PDL1 AI solution for lung cancer, Lunit Insight MMG, and Lunit Insight CT, presented at ASCO GI 2026. Strengthening their presence in the European market

ASCO GI 2026 – Lunit research presentations with AstraZeneca and Gilead Sciences

- Research partnership with Gilead Sciences: Lunit's AI-powered spatial biomarker analysis to be presented at ASCO GI 2026
- Lunit's AI solutions to be presented at ASCO GI 2026
- Lung cancer: Lunit's AI-powered spatial biomarker analysis to be presented at ASCO GI 2026
  - Developed with AstraZeneca
  - Validated with KOREAN GI Cancer Project, a research consortium of Seoul National University Hospital and Seoul National University Bundang Hospital
  - Lunit's AI-powered spatial biomarker analysis to be presented at ASCO GI 2026
- Lung cancer: Lunit's AI-powered spatial biomarker analysis to be presented at ASCO GI 2026
  - Developed with Gilead Sciences
  - Validated with KOREAN GI Cancer Project, a research consortium of Seoul National University Hospital and Seoul National University Bundang Hospital
  - Lunit's AI-powered spatial biomarker analysis to be presented at ASCO GI 2026

2026-03-30 The company presented its latest AI solutions for cancer diagnosis and treatment at the AACR Annual Meeting, held from April 17 to 22, 2026, in Chicago (Apr 20-22), the Company will present lung cancer research, including:

An collaboration with AstraZeneca, the Company applied its Lunit SCORPIO-PDL1 AI solution to lung cancer tissue samples from the KOREAN GI Cancer Project, a research consortium of Seoul National University Hospital and Seoul National University Bundang Hospital. The study evaluated the AI's ability to predict immunotherapy response, as well as some other spatial biomarkers, such as CD8+ lymphocytes, CD8+ PD-L1+ immune cells, and PD-L1+ tumor cells, and their combinations, in patients with non-small cell lung cancer (NSCLC) treated with immunotherapy.

The research centers on the strategic collaboration agreement signed with AstraZeneca in January 2026, which covers the development of AI-powered biomarkers for NSCLC. The goal is to help patients receive more precise and effective treatment.

Lunit's AI-powered spatial biomarker analysis will also be presented at the ASCO GI Symposium, a member of the Illinois Group, evaluating the potential of Lunit SCORPIO-PDL1 AI solution for lung cancer immunotherapy response, in collaboration with Gilead Sciences.

The study applied Lunit SCORPIO-PDL1 AI solution to 2,412 lung cancer FFPE slides from the KOREAN GI Cancer Project, a research consortium of Seoul National University Hospital and Seoul National University Bundang Hospital. The study evaluated the ability of Lunit SCORPIO-PDL1 AI solution to predict immunotherapy response in patients with non-small cell lung cancer (NSCLC).

Based on these findings, the Company will continue refining its AI biomarkers and expanding its research collaborations with pharmaceutical companies and research institutions to support the development of more precise and scalable diagnostic solutions.

Nature Communications: Gastric Cancer in Asian, Multi-Perspective study on assisted image reading improves breast cancer detection without increasing recall rates

2026-03-24 Lunit's AI solutions for cancer diagnosis and treatment have contributed to the advancement of medical research, such as the recent Nature Communications study.

Nature Communications, a leading global scientific journal, published a study on the AI-assisted image reading improves breast cancer detection without increasing recall rates in Asian women, conducted by Seoul National University Bundang Hospital.

A separate simulation showed that their joint application of Lunit INSIGHT MMG and Lunit INSIGHT CXR could reduce the workload of radiologists by approximately 40% while maintaining diagnostic performance.

The research paper concluded that the use of Lunit AI solutions in clinical practice could enhance both diagnostic accuracy and workflow efficiency in breast cancer screening programs.

JCO Precision Oncology: Gastric Cancer in Asia, Expanding potential for AI-based biomarkers

2026-03-24 Lunit's AI solutions, Lunit SCORPIO-MSI, analyzed the treatment response of patients with gastric cancer treated with immunotherapy.

Accounting for about 10% of all cancer cases, gastric cancer is the fourth most common cancer and the third most common cause of cancer-related deaths worldwide. Immunotherapy has emerged as a promising treatment option for this cancer, but only a subset of patients benefit from it. Accurately identifying patients who will respond to immunotherapy remains a critical challenge.

In this study, Lunit SCORPIO-MSI, Lunit's AI-powered biomarker, demonstrated strong performance in predicting response to immunotherapy treatments, including PD-L1 expression and tumor mutational burden (TMB), which are widely used as key biomarkers in immunotherapy treatment decisions.

Based on these findings, the Company will continue refining its AI biomarkers and expanding its research collaborations with pharmaceutical companies and research institutions to support the development of more precise and scalable diagnostic solutions.

Lunit's AI solutions for cancer diagnosis and treatment, including VUNO Med, saw YoY increases of 34%. The growth was driven by the adoption of Lunit Insight MMG and the commercialization of Lunit Insight CT, which contributed KRW 17.1 billion in sales, up from KRW 9.7 billion in 2024.

Attended the World Economic Forum (WEF) in Davos for the 41st consecutive year. Engaged in discussions aimed at the development of AI-driven healthcare solutions and the promotion of global partnerships with Korea's leading pharmaceutical companies

2026-01-23 Lunit's CEO, Suhan Kim, and Lunit's Chief Medical Officer, Hyungsik Kim, participated in the World Economic Forum (WEF) in Davos, Switzerland, from January 19 to 23, 2026, for the 41st consecutive year.

The Company discussed WEF's 2026 theme, "Technology Partnerships" and explored opportunities to strengthen its presence in Korea's healthcare ecosystem. In 2026, Lunit's attendance "Industrial Partnerships" theme, underscoring the growing importance of collaboration between AI companies and traditional industrial firms.

At this year's WEF, Beyondx Ceo, CEO of Lunit, Suhan Kim participated in panel discussions on the theme of "Industrial Partnerships" and shared insights on how AI is being integrated into real-world healthcare systems. The discussion highlighted the growing importance of partnerships between AI companies and traditional industrial companies, as well as the global market landscape, and offered a long-term growth strategy.

The Company also met with pharmaceutical companies and discussed potential collaboration opportunities. Its global commercialization, its strategy centered on strengthening its presence in Korea's healthcare ecosystem, and its long-term growth strategy were also discussed.

Company appointed Gong Seokhwan as new CEO. Internal promotion ensures deep business insight and proven leadership in Korea and Asia

Lunit CEO, Suhan Kim, Attended Davos Meeting. Highlighted Lunit SCORPIO's technological edge and discussed new collaborations with global pharma

2026-01-23 Lunit's CEO, Suhan Kim, and Lunit's Chief Medical Officer, Hyungsik Kim, participated in the World Economic Forum (WEF) in Davos, Switzerland, from January 19 to 23, 2026, for the 41st consecutive year.

The Company discussed WEF's 2026 theme, "Technology Partnerships" and explored opportunities to strengthen its presence in Korea's healthcare ecosystem. In 2026, Lunit's attendance "Industrial Partnerships" theme, underscoring the growing importance of collaboration between AI companies and traditional industrial firms.

At this year's WEF, Beyondx Ceo, CEO of Lunit, Suhan Kim participated in panel discussions on the theme of "Industrial Partnerships" and shared insights on how AI is being integrated into real-world healthcare systems. The discussion highlighted the growing importance of partnerships between AI companies and traditional industrial companies, as well as the global market landscape, and offered a long-term growth strategy.

The Company also met with pharmaceutical companies and discussed potential collaboration opportunities. Its global commercialization, its strategy centered on strengthening its presence in Korea's healthcare ecosystem, and its long-term growth strategy were also discussed.

Company appointed Gong Seokhwan as new CEO. Internal promotion ensures deep business insight and proven leadership in Korea and Asia

DISCLAIMER

Lunit to Expand (the "Website") is a fan-made website dedicated to Lunit (KOSDAQ: 328130), a publicly traded company in South Korea. The Website is not affiliated with, endorsed by, or sponsored by Lunit or any of its subsidiaries or affiliates. The Website is intended for informational purposes only and does not constitute financial advice, investment advice, or any other form of professional advice. The information on the Website may be outdated, incomplete, or inaccurate. Lunit to Expand does not guarantee the accuracy, completeness, or timeliness of the information on the Website. Lunit to Expand disclaims all liability for any losses or damages arising from the use of the Website or reliance on the information on the Website. Visitors should conduct their own research and consult with qualified professionals before making any investment decisions. Lunit to Expand is not responsible for the content of third-party sites linked from the Website. Lunit to Expand reserves the right to modify or remove any content on the Website without prior notice.

Lunit to Expand

For investors, investment inquiries, please contact directly:
Lunit IR Team: ir@lunit.io
Lunit Investor Relations: https://ir.lunit.io/